Cargando…

Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin

Epithelial ovarian cancer (EOC) affects almost 25,000 women annually and is the fifth most common malignancy in women in North America. A combination of surgery and cytotoxic chemotherapy may produce a favorable clinical response. The platinum-paclitaxel combination regimen is the chemotherapy gold-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jinli, Xiong, Xifeng, Hua, Xing, Cao, Wenjuan, Qin, Shengnan, Dai, Libing, Liang, Peihong, Zhang, Huiling, Liu, Zhihe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661610/ https://www.ncbi.nlm.nih.gov/pubmed/29113212 http://dx.doi.org/10.3892/ol.2017.6978

Ejemplares similares

FBP1 promotes ovarian cancer development through the acceleration of cell cycle transition and metastasis
por: Xiong, Xifeng, et al.
Publicado: (2018)

High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity
por: Liu, Wei, et al.
Publicado: (2020)

High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity
por: Liu, Wei, et al.
Publicado: (2021)

Fibrochondrogenic differentiation potential of tendon-derived stem/progenitor cells from human patellar tendon
por: Qin, Shengnan, et al.
Publicado: (2019)

FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3
por: Xiong, Xifeng, et al.
Publicado: (2022)

Amentoflavone triggers cell cycle G2/M arrest by interfering with microtubule dynamics and inducing DNA damage in SKOV3 cells
por: Zhang, Jinli, et al.
Publicado: (2020)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin
por: Zhou, Zhiyang, et al.
Publicado: (2022)

Icariin inhibits the inflammation through down-regulating NF-κB/HIF-2α signal pathways in chondrocytes
por: Wang, Pengzhen, et al.
Publicado: (2020)

Antitumor Activity of the Carboplatin-α-Cyclodextrin Adduct
por: Liu, Weiping, et al.
Publicado: (1997)

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
por: Zhang, Yiping, et al.
Publicado: (2018)

Carboplatin binding to histidine
por: Tanley, Simon W. M., et al.
Publicado: (2014)

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
por: Gorski, Justin W., et al.
Publicado: (2021)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis
por: Wei, Shuqing, et al.
Publicado: (2017)

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin
por: Deng, Minjie, et al.
Publicado: (2019)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer
por: Konstantinopoulos, Panagiotis A, et al.
Publicado: (2008)

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
por: Pénzváltó, Zsófia, et al.
Publicado: (2014)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy
por: Chen, Tao, et al.
Publicado: (2009)

Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53
por: Dixit, Updesh, et al.
Publicado: (2014)

Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer
por: Yang, Xueqing, et al.
Publicado: (2020)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer
por: Mikkelsen, Mette Schou, et al.
Publicado: (2020)

PNMA5 knockdown suppresses the proliferation, invasion, and metastasis of epithelial ovarian cancer cells
por: Qiao, Haifeng, et al.
Publicado: (2020)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Type II Collagen Sponges Facilitate Tendon Stem/Progenitor Cells to Adopt More Chondrogenic Phenotypes and Promote the Regeneration of Fibrocartilage-Like Tissues in a Rabbit Partial Patellectomy Model
por: Wang, Wen, et al.
Publicado: (2021)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study
por: Paksoy, Nail, et al.
Publicado: (2022)

Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid
por: Xiong, Xifeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7472kvi9k76jhb5l0jeaeo9d25